UK Home Office bans Animal Testing of Household Products
The Rt Hon Lynne Featherstone MP announced on Thursday 12th March 2015 that the UK will ban testing of households products on animals. The ban will come into force in October 2015 and will cover all finished products including detergents, polishes and cleaning products, laundry products, air fresheners, deodorants, paints and other decorating materials. The testing requirements only apply to ingredients which make up >50% of the finished household product. Although the ban is a welcome first step to reducing animal testing, campaign groups feel the regulation should be stricter and apply to any ingredients within household products.
The full announcement can be found on the UK Government website:
To address the new regulations, Cyprotex offer a range of skin and ocular methods as in vitro alternative tests for assessing potential toxicity of household products.
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.